CJC-1295 No DAC + Ipamorelin

Complementary GHRH-receptor and GHSR signaling

Two-component research blend

Investigational research blend; the exact commercial combination lacks robust direct clinical validation

Overview

CJC-1295 No DAC + Ipamorelin combines two research compounds that act through different upstream pathways of growth-hormone release. “CJC-1295 No DAC” is commonly used in the research market to describe a short-acting modified GHRH(1-29)-type analog, while ipamorelin is a ghrelin/growth-hormone-secretagogue receptor agonist. The scientific rationale is complementary signaling at the pituitary: one component activates the GHRH receptor and the other activates GHSR. Evidence for each mechanism exists, but data on the exact Apex commercial blend should not be assumed from studies of CJC-1295 with DAC or from the individual ingredients alone.

How it works

checkCreated with Sketch.

GHRH receptor pathway: The CJC/modified-GRF component acts through pituitary GHRH receptors.

checkCreated with Sketch.

GHSR pathway: Ipamorelin acts through the growth-hormone-secretagogue/ghrelin receptor.

checkCreated with Sketch.

Complementary pituitary signaling: Research interest centers on whether concurrent upstream signals alter GH pulse amplitude or timing compared with either pathway alone.

Research areas

checkCreated with Sketch.

Growth-hormone pulse physiology

checkCreated with Sketch.

GHRH receptor signaling

checkCreated with Sketch.

Ghrelin/GHSR signaling

checkCreated with Sketch.

Combination endocrine pharmacology

Research / study context

one

CJC-family research: Human studies of long-acting CJC-1295 demonstrate GHRH-receptor pharmacology, but those data are not identical to No-DAC material.

two

Ipamorelin pharmacology: Human and preclinical studies demonstrate GHSR-mediated growth-hormone release and endocrine selectivity.

three

Exact-combination evidence: Robust controlled human evidence for the exact CJC-1295 No DAC + Ipamorelin commercial blend is limited; present component evidence separately.

Key research findings

checkCreated with Sketch.

The components act through distinct but converging pituitary pathways.

checkCreated with Sketch.

Direct evidence for the exact blend is weaker than evidence for the individual mechanisms.

checkCreated with Sketch.

Do not describe the blend as clinically proven for anti-aging, fat loss, muscle growth, or recovery.

Scientific reference starter set

one

Peptide Education Hub: CJC-1295 + Ipamorelin profile (secondary reference)

two

PubMed search: CJC-1295 GHRH analog healthy adults

three

PubMed search: ipamorelin selective growth hormone secretagogue

Research material

View available specifications and batch documentation in the Apex catalog.

Important

For research use only. Not for human consumption. This profile is educational and does not provide treatment or personal-use instructions.